About 2,000 women with vulvovaginal candidosis were included in clinical, mostly multicentric studies with terconazole formulations applicable by the vaginal route. In addition to these clinical studies, more basic studies were performed between 1980 and 1982. 1,179 subjects were treated with vaginal suppositories 240, 80, and 40 mg, as well as with cream 0.8 and 0.4%. Comparative studies with other terconazole formulations or with other antimycotics were carried out on 767 patients altogether. Data on therapeutic effect and tolerability for the test population mentioned above have been compiled. The mycological cure rates obtained with each of the five treatment schedules (1-day to 7-day therapy) reached 90%. Follow-up examinations revealed clinical signs of vulvovaginal inflammation, i.e., vulvar (vaginal) erythema in about 10% of the women. One to three per cent of the women treated complained, mostly after the first application of terconazole, of transient burning. The data obtained confirm the high antimycotic potency and the therapeutic effect of terconazole as well as the excellent topical tolerability of the dosage forms tested.

Keywords:
Terconazole, Vulvovaginal candidosis
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.